Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
They are frequently studied in combination protocols
In a subanalysis of SURPASS-3, tirzepatide 10 and 15 mg resulted also in a relative reduction in liver fat content by 4047% compared to 11% with insulin glargine at 52 weeks [44]
Always refer to the specific BUD provided by your pharmacy, as they have tested the stability of their specific oral formulation, which may differ from injectable standards
US$ 27.03
US$ 24.05
US$ 28.69
